Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIB Multicentre Open Label 54 Weeks Clinical Trial Evaluating Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor Alpha (TNFα) on Endoscopic and Mucosal Healing in Patients Suffering From Active Crohn's Disease.

NCT00297648 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT00297648
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00297648 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIB Multicentre Open Label 54 Weeks Clinical Trial Evaluating Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor Alpha (TNFα) on Endoscopic and Mucosal Healing in Patients Suffering From Active Crohn's Disease.
Lead sponsor
UCB Pharma
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2006
Completion date
December 31, 2009
Enrollment
89 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease